Study of the Immune Response in Colon Adenocarcinoma

Institut National de la Santé Et de la Recherche Médicale, France100 enrolled

Overview

Duration of each part of the study per patient: * Screening: From 1 to 4 weeks * Sampling period (blood and tissue): 1 day * Follow-up by patient: 60 months * Total study duration by patient: 84 months * Total inclusion duration: 24 months * Total Follow-up duration: 60 months * Total study duration: 84 months

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Colon Adenocarcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients aged 18 or more. 2. Affiliation to a social security scheme 3. Diagnosis of a colon adenocarcinoma. 4. Patient have signed and dated consent of the study before undertaking procedures related to the study. Exclusion Criteria: 1. Patients under guardianship / curatorship 2. Following Situations * Persons unable to understand, read and / or sign an informed consent * Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study * Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year. * No affiliation to a social security scheme, a universal medical coverage or any similar plan. 3. Pregnant or lactating women. 4. Patients with HIV seropositivity. 5. Rectal tumor location.

Locations (1)

Hôpital Saint Louis

Paris, France

Outcomes

Primary Outcomes

Immune cells trafficking

Frequency of T cells in the blood and tissue (Flow cytometry method with a panel of Ab).

Time frame: Day 0

Secondary Outcomes

Infiltration of leucocytes in tumor tissue

Histochemical method with a panel of Ab.

Time frame: Day 0

Safety (Number of adverse events, ECOG status)

Time frame: After Day 0 until the end of the study (Month 3, Month 6, Month 9, Month 12, Month 15, Month 18,Month 21, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54 and Month 60)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.